Malignant pleural mesothelioma continues to be a challenging tumor to
image and treat. A multimodality multidisciplinary team approach including surgery,
oncology, radiology and radiation therapy is required for successful outcomes. Reliable
and reproducible methods of assessing treatment response are crucial for guiding
management, whether for clinical practice, research, or to meet the requirements of a
clinical trial. Computed Tomography is the first line imaging modality due to its superb
spatial resolution and volumetric data set, allowing for 3D reconstructions that aid in
tumor volume assessment and surgical planning. MRI has the potential to provide
qualitative, quantitative, anatomical and functional information without the use of
ionizing radiation or intravenous contrast administration. Newer advances and
optimization of existing protocols can help identify imaging biomarkers that can serve
as surrogates of survival.
Keywords: ADC, DCE-MRI, DWI, Mesothelioma, RECIST, tumor volume.
